郭雪原,董建增,龙德勇,喻荣辉,汤日波,白融,刘念,桑才华,蒋晨曦,李松南,马长生

• 1:首都医科大学附属北京安贞医院心内科

摘要(Abstract)：

目的评价既往颅内出血的心房颤动患者接受导管消融的安全性和有效性。方法连续入选2007年1月至2014年12月在北京安贞医院接受心房颤动导管消融且既往有颅内出血病史的患者22例。所有患者接受导管消融治疗,围术期采取停用华法林,应用低分子肝素抗凝。随访术后心律失常复发情况和临床预后。结果所有患者围术期均未发生严重出血或栓塞事件。1例患者术后发生心脏压塞,2例患者出现血管并发症。平均随访(28.9±10.7)个月,15例(68.2%)患者初次消融后维持窦性心律,2例(9.1%)复发患者接受再次消融后成功维持窦性心律,总体窦性心律维持率77.3%。所有患者术后均停用华法林,随访期间无栓塞和出血事件发生。结论既往有颅内出血病史的心房颤动患者接受导管消融是安全有效的,术后维持窦性心律可避免抗凝药物使用带来的出血风险。

关键词(KeyWords)： 心房颤动;导管消融;颅内出血;抗凝治疗

Abstract:

Keywords:

基金项目(Foundation): 科技部国际合作项目(2013DFB30310)

作者(Author): 郭雪原,董建增,龙德勇,喻荣辉,汤日波,白融,刘念,桑才华,蒋晨曦,李松南,马长生

参考文献(References)：

• [1]Hart RG,Pearce LA,Aguilar MI.Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.Ann Intern Med,2007,146(12):857-867.
• [2]Gage BF,Yan Y,Milligan PE,et al.Clinical classification schemes for predicting hemorrhage:results from the National Registry of Atrial Fibrillation(NRAF).Am Heart J,2006,151(3):713-719.
• [3]桑才华,董建增,龙德勇,等.不同抗凝策略对心房颤动导管消融心脏压塞并发症处理的影响.中国介入心脏病学杂志,2014,22(4):210-214.
• [4]李松南,董建增,王璐,等.肺癌外科术后合并心房颤动患者的导管消融治疗.中国介入心脏病学杂志,2015,23(4):187-191.
• [5]Goldstein JN,Greenberg SM.Should anticoagulation be resumed after intracerebral hemorrhage?Cleve Clin J Med,2010,77(11):791-799.
• [6]Shen AY,Yao JF,Brar SS,et al.Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation.J Am Coll Cardiol,2007,50(4):309-315.
• [7]Horstmann S,Rizos T,Jenetzky E,et al.Prevalence of atrial fibrillation in intracerebral hemorrhage.Eur J Neurol,2014,21(4):570-576.
• [8]Claassen DO,Kazemi N,Zubkov AY,et al.Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage.Arch Neurol,2008,65(10):1313-1318.
• [9]Steiner T,Kaste M,Forsting M,et al.Recommendations for the management of intracranial haemorrhage-part I:spontaneous intracerebral haemorrhage.The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee.Cerebrovasc Dis,2006,22(4):294-316.
• [10]Karasoy D,Gislason GH,Hansen J,et al.Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding:long-term followup in nationwide cohort of Denmark.Eur Heart J,2015,36(5):307-314a.
• [11]Calkins H,Kuck KH,Cappato R,et al.2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation:recommendations for patient selection,procedural techniques,patient management and followup,definitions,endpoints,and research trial design:a report of the Heart Rhythm Society(HRS)Task Force on Catheter and Surgical Ablation of Atrial Fibrillation.Developed in partnership with the European Heart Rhythm Association(EHRA),a registered branch of the European Society of Cardiology(ESC)and the European Cardiac Arrhythmia Society(ECAS);and in collaboration with the American College of Cardiology(ACC),American Heart Association(AHA),the Asia Pacific Heart Rhythm Society(APHRS),and the Society of Thoracic Surgeons(STS).Endorsed by the governing bodies of the American College of Cardiology Foundation,the American Heart Association,the European Cardiac Arrhythmia Society,the European Heart Rhythm Association,the Society of Thoracic Surgeons,the Asia Pacific Heart Rhythm Society,and the Heart Rhythm Society.Heart Rhythm,2012,9(4):632-696.
• [12]Nairooz R,Ayoub K,Sardar P,et al.Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation:A Meta-analysis.Can J Cardiol,2016,32(6):814-823.
• [13]Rillig A,Lin T,Plesman J,et al.Apixaban,Rivaroxaban,and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.J Cardiovasc Electrophysiol,2016,27(2):147-153.